Immunotherapy with chemotherapy for recurrent cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of three drugs—camrelizumab (an immunotherapy that helps your immune system fight cancer), famitinib (a targeted therapy that blocks blood vessel growth to tumors), and standard chemotherapy—for cervical cancer that has come back or spread and cannot be removed with surgery or radiation. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- Your cervical cancer is squamous cell, adenocarcinoma, or adenosquamous cell and has returned or spread, and cannot be cured with surgery, radiation, or chemoradiation.
- You have not had any previous systemic treatment (like chemotherapy or targeted therapy) for your recurrent or metastatic cancer.
- You have at least one tumor that can be measured on a scan.
- You are able to swallow tablets and have adequate organ function, and you are physically active (able to do light housework or office work).
- You do not have brain metastases, autoimmune diseases, or another cancer in the past 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (nimotuzumab and tislelizumab) alongside radiation therapy for people whose cervical cancer has returned or spread to a few other places. The goal is to see if this approach can help control the cancer better and improve survival.
This study tests a combination of two drugs (camrelizumab and famitinib) given after surgery for early-stage cervical cancer. The goal is to see if this treatment helps keep the cancer from returning. It is for people who have not had any other cancer treatment yet.
This trial tests a new treatment that combines an immunotherapy drug (cadonilimab) with chemotherapy for people with locally advanced cervical cancer. The goal is to see if this combination can shrink the tumor enough to make surgery possible or more effective.
This Phase 2 trial tests cadonilimab (an immunotherapy medicine) combined with anlotinib (a targeted drug) for advanced or recurrent cervical cancer that has already been treated. It may help shrink tumors or slow cancer growth, especially if the cancer has a measurable area doctors can track.
This trial tests a combination of chemotherapy and immunotherapy for patients with cervical cancer that has spread to pelvic lymph nodes (stage IIICp) after radical surgery. It aims to improve outcomes by boosting the immune system's ability to fight remaining cancer cells.
This study tests whether combining immunotherapy with chemotherapy, followed by radiation plus immunotherapy, can work better than standard treatment for cervical cancer. It aims to help patients whose cancer has not spread yet.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.